Novo Nordisk A/S
NONOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,558,094 | $1,955,495 | $2,111,870 | $2,755,596 |
| - Cash | $32,084 | $18,435 | $38,938 | $15,655 |
| + Debt | $101,214 | $99,268 | $118,723 | $102,787 |
| Enterprise Value | $1,627,224 | $2,036,328 | $2,191,655 | $2,842,728 |
| Revenue | $74,976 | $76,857 | $78,087 | $85,683 |
| % Growth | -2.4% | -1.6% | -8.9% | – |
| Gross Profit | $57,072 | $64,011 | $65,197 | $72,659 |
| % Margin | 76.1% | 83.3% | 83.5% | 84.8% |
| EBITDA | $33,761 | $43,596 | $46,046 | $40,142 |
| % Margin | 45% | 56.7% | 59% | 46.8% |
| Net Income | $20,006 | $26,503 | $29,034 | $28,230 |
| % Margin | 26.7% | 34.5% | 37.2% | 32.9% |
| EPS Diluted | 4.5 | 5.96 | 6.53 | 6.33 |
| % Growth | -24.5% | -8.7% | 3.2% | – |
| Operating Cash Flow | $46,107 | $40,785 | $24,591 | $12,301 |
| Capital Expenditures | -$13,628 | -$16,275 | -$14,586 | -$16,558 |
| Free Cash Flow | $32,479 | $24,510 | $10,005 | -$4,257 |